Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruiting · NCT07510100 · Registry updated 2026-04-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-04-03 | NCT07510100 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing IASO Biotechnology Co., Ltd. | 14 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Science Tokyo Hospital | Bunkyo-Ku | Japan | 7 |
| Japanese Red Cross Medical Center | Shibuya-ku | Japan | 9 |
| Nihon University Itabashi Hospital | Itabashi-ku | Japan | 4 |